Pacific Biosciences of California, Inc.
PACB
$1.37
-$0.01-0.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.18M | 44.65M | 38.44M | 39.77M | 37.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.18M | 44.65M | 38.44M | 39.77M | 37.15M |
| Cost of Revenue | 23.65M | 40.29M | 22.28M | 24.88M | 30.11M |
| Gross Profit | 13.52M | 4.36M | 16.16M | 14.89M | 7.04M |
| SG&A Expenses | 31.15M | 35.75M | 31.10M | 36.18M | 40.17M |
| Depreciation & Amortization | 1.02M | 1.02M | 1.02M | 1.02M | 366.39M |
| Other Operating Expenses | -- | 4.18M | -- | -- | 4.07M |
| Total Operating Expenses | 75.43M | 104.71M | 77.24M | 84.60M | 469.79M |
| Operating Income | -38.25M | -60.06M | -38.80M | -44.83M | -432.63M |
| Income Before Tax | -8.09M | -40.17M | -37.62M | -41.90M | -426.38M |
| Income Tax Expenses | 184.00K | 202.00K | 383.00K | 35.00K | -302.00K |
| Earnings from Continuing Operations | -8.28M | -40.37M | -38.00M | -41.93M | -426.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.28M | -40.37M | -38.00M | -41.93M | -426.08M |
| EBIT | -38.25M | -60.06M | -38.80M | -44.83M | -432.63M |
| EBITDA | -35.03M | -56.31M | -35.32M | -41.15M | -61.11M |
| EPS Basic | -0.03 | -0.13 | -0.13 | -0.14 | -1.44 |
| Normalized Basic EPS | -0.08 | -0.11 | -0.08 | -0.09 | -0.91 |
| EPS Diluted | -0.03 | -0.13 | -0.13 | -0.14 | -1.44 |
| Normalized Diluted EPS | -0.08 | -0.11 | -0.08 | -0.09 | -0.91 |
| Average Basic Shares Outstanding | 305.82M | 301.91M | 300.84M | 300.16M | 296.86M |
| Average Diluted Shares Outstanding | 305.82M | 301.91M | 300.84M | 300.16M | 296.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |